Literature DB >> 34547323

Orodispersible films: Conception to quality by design.

Maram Suresh Gupta1, Tegginamath Pramod Kumar2, Devegowda Vishkante Gowda2, Jessica M Rosenholm3.   

Abstract

Orodispersible films (ODFs) are ultra-thin, stamp-sized, elegant, portable and patient-centric pharmaceutical dosage forms that do not need water to be ingested. They are particularly useful for paediatric and geriatric patient populations with special needs such as dysphagia, Parkinson's disease, and oral cancer. Accordingly, they hold tremendous potential in gaining patient compliance, convenience and pharmacotherapy. In the present review, conception and evolution of ODFs as a product and its technology are discussed. The review continues by providing overview about the potential of ODFs as carriers for delivering drugs, herbal extracts, probiotics and vaccines. Besides, strategies employed in drug cargo loading, taste masking of bitter drugs and enhancing drug stability are discussed. Finally, the review concludes by providing a brief overview about quality by design (QbD) principles in development of ODFs.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ODF; Patient-centric; Probiotics; QbD; Quality by design; Vaccines

Mesh:

Substances:

Year:  2021        PMID: 34547323     DOI: 10.1016/j.addr.2021.113983

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  2 in total

Review 1.  A Comprehensive Review of Patented Technologies to Fabricate Orodispersible Films: Proof of Patent Analysis (2000-2020).

Authors:  Maram Suresh Gupta; Devegowda Vishakante Gowda; Tegginamath Pramod Kumar; Jessica M Rosenholm
Journal:  Pharmaceutics       Date:  2022-04-08       Impact factor: 6.525

Review 2.  Orally Dispersible Dosage Forms for Paediatric Use: Current Knowledge and Development of Nanostructure-Based Formulations.

Authors:  Andreea Cornilă; Sonia Iurian; Ioan Tomuță; Alina Porfire
Journal:  Pharmaceutics       Date:  2022-08-03       Impact factor: 6.525

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.